TABLE 5.
Summary of results after discordant analysisa
| Assay | No. of samples with result
|
% Sens | % Spec | PPV (%) | NPV (%) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pos/Neg (total)b | True Posb | False Posc | True Negb | False Negc | |||||
| IHPV (w/o 66) | 365/392 | 350 | 9 | 368 | 15 | 95.89 | 97.61 | 97.49 | 96.08 |
| IHPV (with 66) | 380/377 | 350 | 9 | 338 | 30 | 92.11 | 97.41 | 97.49 | 91.85 |
| HC2 (w/o 66) | 365/392 | 358 | 53 | 330 | 7 | 98.08 | 86.16 | 87.10 | 97.94 |
| HC2 (with 66) | 380/377 | 373 | 38 | 330 | 7 | 98.16 | 89.67 | 90.75 | 97.94 |
“w/o 66” (rows 1 and 3) indicates analysis without including data for type 66. Data are presented based upon detection of HR HPV types in accordance with type-specific probes present in each assay. “with 66” (rows 2 and 4) indicates that data are presented including detection of HR HPV type 66 due to HC2 probe cross-reactivity, since samples were scored as positive with the HC2 assay and confirmed by PCR/sequencing to contain type 66. Pos, positive; Neg, negative; Sens, sensitivity;. Spec, specificity.
Total true-positive and true-negative samples were determined based upon concordant HC2/IHPV testing and discordant analysis.
Samples were scored as false positive or false negative if results were not concordant between IHPV, HC2, and sequencing.